NSE: MANKIND | BSE: 543904

Expensive Underperformer

Download real time

2151.90 4.90 (0.23%)

New 52W Low in past week

18,012 NSE+BSE Volume

NSE 23 Jan, 2026 9:34 AM (IST)

88,831.5

Market Cap

High in industry

Beta 1Year

Very Low volatility

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Search Inside the pdf :

Mankind Pharma Ltd.

16 Dec 2025

2151.90

0.23%

BP Equities Mankind Pharma Initiating Coverage BUY Target 2,652

Buy: Mankind Pharma Ltd.

BP Wealth

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

26 Nov 2025

2151.90

0.23%

MANKIND PHARMA LIMITED

Buy: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in New Delhi. The company has products in therapeutic areas...

Mankind Pharma Ltd. has an average target of 2684.00 from 3 brokers.

Mankind Pharma Ltd.

07 Nov 2025

2151.90

0.23%

2Q in line; transition phase underway

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered a largely in-line financial performance for 2QFY26. EBITDA was slightly lower than estimates due to higher employee costs.

Number of FII/FPI investors decreased from 627 to 575 in Dec 2025 qtr

Mankind Pharma Ltd.

01 Aug 2025

2151.90

0.23%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

22 May 2025, 12:00AM

2151.90

0.23%

Higher marketing/promotional costs drive a miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line revenue in 4QFY25; however, EBITDA/PAT came in 14%/12% below our estimates. Higher-than-expected spending on marketing and promotional activities affected the company’s 4Q performance.

Number of FII/FPI investors decreased from 627 to 575 in Dec 2025 qtr

Mankind Pharma Ltd.

26 Mar 2025

2151.90

0.23%

MANKIND PHARMA LIMITED

Accumulate: Mankind Pharma Ltd.

Geojit BNP Paribas

Number of FII/FPI investors decreased from 627 to 575 in Dec 2025 qtr

Mankind Pharma Ltd.

25 Jan 2025

2151.90

0.23%

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line operational performance for 3QFY25. The earnings were below estimates due to higher interest outgo on debt raised to fund the BSV acquisition.

Mankind Pharma Ltd. has an average target of 2684.00 from 3 brokers.

Mankind Pharma Ltd.

05 Nov 2024

2151.90

0.23%

Superior execution in consumer wellness/exports drives beat on 2Q estimates

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business.

Mankind Pharma Ltd. has an average target of 2684.00 from 3 brokers.

Mankind Pharma Ltd.

23 Aug 2024, 12:00AM

2151.90

0.23%

FundsIndia

Number of FII/FPI investors decreased from 627 to 575 in Dec 2025 qtr

Mankind Pharma Ltd.

23 Aug 2024, 12:00AM

2151.90

0.23%

Improvising the base; adding new avenues for growth

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-the counter (OTC) space.